Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 4, 1996, Pages 273-310

  Iwatsubo, Takafumi ^a   Hirota, Noriko ^a   Ooie, Tsuyoshi ^a   Suzuki, Hiroshi ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

drug disposition; in vitro; in vivo; physiological pharmacokinetics; prediction

Indexed keywords

ALPRENOLOL; CARBAMAZEPINE; DIAZEPAM; ETHENZAMIDE; HEXOBARBITAL; HYMECROMONE; LIDOCAINE; PETHIDINE; PHENACETIN; PHENAZONE; PHENYTOIN; PROPRANOLOL; SEROTONIN; THIOPENTAL; TOLBUTAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER FUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RAT; REVIEW; THEORETICAL STUDY;

ANIMALS; HUMANS; MALE; MODELS, BIOLOGICAL; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 0029950964     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199605)17:4<273::AID-BDD961>3.0.CO;2-R     Document Type: Review

References (123)

1. K. B. Bischoff and R. L. Dedrick, Thiopental pharmacokinetics. J. Pharm. Sci., 57,1346-1351 (1964).
2. M. Gibaldi and D. Perrie, Physiological pharmacokinetic models. In Pharmacokinetics, Dekker, New York, 1982, pp. 355-384.
3. M. Rowland, L. Z. Benet and G. G. Graham, Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm., l, 123-136(1973).
4. K. S. Pang and M. Rowland, Hepatic clearance of drugs: I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 5, 625-653 (1977).
5. R. L. Dedrick, K. B. Bischoff and D. S. Zaharko, Inter-species correlation of plasma concentration history of methotrexate. Cancer Chemother. 1, 52, 95-101 (1970).
6. R. L. Dedrick, Animal scale-up. J. Pharmacokinet. Biopharm., 1, 435-461 (1973).
7. H. Boxenbaum, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm., 8, 165-176 (1980).
8. H. Boxenbaum, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm., 10, 201-227 (1982).
9. H. Boxenbaum, Comparative pharmacokinetics of benzodiazepines in dog and man. J. Pharmacokinet. Biopharm., 10, 411-426 (1982).
10. Y. Sawada, M. Hanano, Y. Sugiyama and T. Iga, Prediction of the disposition of β-lactam antibiotics in human from pharmacokinetic parameters in animals. J. Pharmacokinet. Biopharm., 12, 241-261 (1984).
11. S. Toon and M. Rowland, Structure-pharmacokinetic relations among the barbiturates in the rat. J. Pharmacol. Exp. Ther., 225, 752-763 (1983).
12. G. R. Wilkinson and D. G. Shand, A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther., 18, 377-390 (1975).
13. G. R. Wilkinson, Clearance approaches in pharmacology. Pharmacol. Rev., 39, 1-47 (1987).
14. M. Hanano, J. H. Lin, Y. Sugiyama and S. Awazu, In Proceedings of the Kyoto International Conference against Drug-induced Sufferings, T. Soda (Ed.), Excerpta Medica, 1979, pp. 62-67.
15. A. Rane, G. R. Wilkinson and D. G. Shand, Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther., 200, 420-424 (1977).
16. J. B. Houston, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 47, 1469-1479 (1994).
17. K. S. Pang and M. Chiba, Metabolism: Scaling-up from In Vitro to Organ and Whole Body. In Handbook of Experimental Pharmacology, P. G. Welling and L. P. Balaut (Eds), Springer, 1994, pp. 101-187.
18. M. Gibaldi and D. Perrier, Clearance concepts. In Pharmacokinetics, Dekker, New York, 1982, pp. 319-353.
19. L. Bass and S. Keiding, Physiologically based models and strategic experiments in hepatic pharmacology. Biochem. Pharmacol., 37, 1425-1431 (1988).
20. M. S. Roberts and M. Rowland, A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm., 14, 227-260 (1986).
21. L. Bass, P. Robinson and A. J. Bracken, Hepatic elimination of flowing substrates: the distributed model. J. Theor. Biol., 72, 161-184 (1978).
22. L. Bass, Saturation kinetics in hepatic drug removal: a statistical approach to functional heterogeneity. Am. J. Physiol., 244, G583-589 (1983).
23. Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, Reconstruction of in vivo metabolism from in vitro data. In Xenobiotic Metabolism and Disposition; Proceedings of the 2nd International ISSX Meeting, R. Kato, R. W. Estabrook and M. N. Cayen (Eds), Taylor and Francis, London, 1989, pp. 225-235.
24. M. S. Roberts and M. Rowland, Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J. Pharm. Pharmacol., 38, 177-181 (1986).
25. Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model. J. Pharmacokinet. Biopharm., 11, 577-593 (1983).
26. J. H. Lin, Y. Sugiyama, S. Awazu, M. Hanano, Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm., 10, 649-661 (1982).
27. Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat. J. Pharmacokinet. Biopharm., 10, 53-75 (1982).
28. O. Sugita, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Physiologically based pharmacokinetics of drug-drug interaction: A study of tolbutamide-sulfonamide interaction in rats. J. Pharmacokinet. Biopharm., 10, 297-316 (1982).
29. K. S. Pang and M. Rowland, Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel-tube" model using lidocaine in the perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm., 5, 655-680 (1977).
30. A. B. Ahmad, P. N. Bennett and M. Rowland, Models of hepatic drug clearance: discrimination between the 'well-stirred' and 'parallel-tube' models. J. Pharm. Pharmacol., 35, 219-224 (1983).
31. D. B. Jones, D. J. Morgan, G. W. Mihaly, L. K. Webster and R. A. Smallwood, Discrimination between the venous equilibrium and sinusoidal models of hepatic drug elimination in the isolated perfused rat liver by perturbation of propranolol protein binding. J. Pharmacol. Exp. Ther., 229, 522-526 (1984).
32. L. Bass, Flow dependence of first order uptake of substances by heterogeneous perfused organs. J. Theor. Biol., 86, 365-376 (1980).
33. E. L. Forker and B. A. Luxon, Albumin binding and hepatic uptake: the importance of model selection. J. Pharm. Sci., 72, 1232-1233 (1983).
34. Y. Sawada, Y. Sugiyama, Y. Miyamoto, T. Iga and M. Hanano, Hepatic drug clearance model: Comparison among the distributed, parallel-tube and well-stirred models. Chem. Pharm. Bull., 33, 319-326 (1985).
35. J. H. Lin, Y. Sugiyama, S. Awazu and M. Hanano, Kinetic studies on the deethylation of ethoxybenzamide: A comparative study with isolated hepatocytes and liver microsomes of rat. Biochem. Pharmacol., 29, 2825-2830 (1980).
36. O. Sugita, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. Biochem. Pharmacol., 30, 3347-3354 (1981).
37. Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, In vitro and in vivo assessment of hepatic and extrahepatic metabolism of diazepam in the rat. J. Pharm. Sci., 73,826-828 (1984).
38. T. Seddon, I. Michelle and R. J. Chenery, Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem. Pharmacol., 38, 1657-1665 (1989).
39. M. H. Grant, M. D. Burke, G. M. Hawksworth, S. J. Duthie, J. Engeset and J. C. Petrie, Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. Biochem. Pharmacol., 36, 2311-2316 (1987).
40. M. K. Bayliss, J. A. Bell, W. N. Jenner and K. Wilson, Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. Biochem. Soc. Trans., 18, 1198-1199(1990).
41. F. Broly, C. Libersa and M. Lhermitte, Mexiletine metabolism in vitro by human liver. Drug Metab. Disposit., 18, 362-368 (1990).
42. R. A. Robson, A. P. Matthews, J. O. Miners, M. E. McManus, U. A. Meyer, P. M. Hall and D. J. Birkett, Characterisation of theophylline metabolism in human liver microsomes. Br. J. Clin. Pharmacol, 24, 293-300 (1987).
43. F. Jacolot, I. Simon, Y. Dreano, P. Beaune, C. Riche and F. Berthou, Identification of cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41, 1911-1919 (1991).
44. B. Richard, G. Fabre, G. D. Sousa, I. Fabre, R. Rhamani and J. P. Cano, Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and human. Biochem. Pharmacol., 41, 255-262 (1991).
45. H. K. Kroemer, H. Echizen, H. Heidemann, M. Eichelbaum, Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther., 260, 1052-1057 (1992).
46. R. B. Smith, P. D. Kroboth, J. T. Vanderlugt, J. P. Phillips and R. P. Juhl, Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology, 84, 452-456 (1984).
47. 14C-alprazolam, a new anxiolytic-antidepressant, in man. Pharmacologist, 22, 279 (1980).
48. L. von Moltke, D. J. Greenblatt, J. S. Harmatz and R. I. Shader, Alprazolam metabolism in vitro: Studies of human, monkey, mouse and rat liver microsomes. Pharmacology, 47, 268-276 (1993).
49. U. Klotz, K. H. Antonin and P. R. Bieck, Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J. Pharmacol. Exp. Ther., 199, 67-73 (1976).
50. D. A. Smith, H. S. Rasmussen, D. A. Stopher and D. K. Walker, Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica, 22, 709-719 (1992).
51. D. A. Ciraulo, J. G. Barnhill and J. H. Jaffe, Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers, Clin. Pharmacol. Ther., 43, 509-518 (1988).
52. K. Chiba, A. Saitoh, E. Koyama, M. Tani, M. Hayashi and T. Ishizaki, The role of mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: twoenzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br. J. Clin. Pharmacol., 37, 237-242 (1994).
53. L. M. H. Wing, J. O. Miners, D. J. Birkett, D. Phill, T. Foenannder, K. Lillywhite and S. Wanwimolruk, Lidocaine disposition - Sex difference and effects of cimetidine. Clin. Pharmacol. Ther., 35, 695-701 (1984).
54. R. P. Remmel, A. K. Copa and D. M. Angaran, The effects of hemodilution pH and protamine on lidocaine plasma protein binding and red blood-cell uptake in vitro. Pharm. Res., 8,127-130 (1991).
55. J. B. Keenaghan and R. N. Boyes, The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J. Pharmacol. Exp. Ther., 180, 454-463 (1972).
56. M. J. Bargetzi, T. Aoyama, F. J. Gonzalez and U. A. Meyer, Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther., 46, 521-527 (1989).
57. L. J. Schaaf, S. C. Cambell, M. B. Mayersohn, T. Vagedes and D. G. Perrier, Influence of smoking and gender on the disposition kinetics of metoprolol. Eur. J. Clin. Pharmacol., 33, 355-361 (1987).
58. C. P. Quarterman, M. J. Kendall and D. B. Jack, The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br. J. Clin. Pharmacol., 11, 287-294 (1981).
59. C. G. Regardh, K. O. Borg, R. Johansson and L. Palmer, Pharmacokinetics studies on the selective bl-receptor antagonist metoprolol in man. J. Pharmacokinet. Biopharm., 2, 347-364 (1974).
60. K. A. Johansson, C. Appelgern, K. O. Borg and R. Elofsson, Binding of two adrenergic betareceptor antagonists, alprenolol and H 93/26, to human serum proteins. Acta. Pharm. Suecica, 11, 333-346 (1974).
61. M. Kim, D. D. Shen, A. C. Eddy and W. L. Nelson, Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab. Disposit., 21, 309-317(1992).
62. L. F. Prescott, J. A. Clements and A. Pottage, Absorption, distribution and elimination of mexiletine. Postgrad. Med. J., 53 (Suppl. 1), 50-55 (1977).
63. J. Turgeon, O. Grech-belanger and M. Gilbert, Erythrocyte and serum distribution of mexiletine in man. Biopharm. Drug Disposit., 8, 571-576 (1987).
64. P. J. Pentikäinen, M. O. Halinen and M. J. Helin, Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. Eur. J. Clin. Pharmacol., 25, 773-777 (1983).
65. A. H. Beckett and E. C. Chidomere, The distribution, metabolism and excretion of mexiletine in man. Postgrad. Med. J., 53 (Suppl. 1), 60-66 (1977).
66. J. Raaflaub and U. C. Dubach, On the pharmacokinetics of phenacetin in man. Ear. J. Clin. Pharmacol., 8, 261-265 (1975).
67. 14C]-acetylphenacetin. Xenobiotica, 4, 489-501 (1974).
68. E. S. Vesell, G. T. Passananti, P. A. Glenwright and B. H. Dovrchik, Studies on the disposition of antipyrine, aminopyrine and phenacetin using plasma, saliva and urine. Clin. Pharmacol. Ther., 18, 259-272 (1975).
69. G. Mikus, H. R. Ha, S. Vozeh, F. Zekorn, F. Follath and M. Eichelbaum, Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur. J. Clin. Pharmacol., 31, 69-72 (1986).
70. V. C. Yu, E. D. Lamirande, M. G. Horning and K. S. Pang, Dose-dependent kinetics of quinidine in the perfused rat liver preparation. Kinetics of formation of active metabolites. Drug Metab. Disposit., 10, 568-572 (1982).
71. B. G. Hardy and J. Schentag, Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int. J. Clin. Pharmacol. Ther. Toxicol., 26, 388-391 (1988).
72. S. V. Otton, R. U. Brinn and L. F. Gram, In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab. Disposit., 16, 15-17 (1987).
73. P. A. Mitenko and R. I. Ogillvie, Pharmacokinetics of intravenous theophylline. Clin. Pharmacol. Ther., 14, 509-513 (1973).
74. T. J. Monks, R. L. Smith and J. Caldwell, A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine). J. Pharm. Pharmacol., 163, 351-362(1979).
75. K. Piafsky, D. S. Sitar, R. E. Rangno and R. I. Ogillvie, Theophylline disposition in patients with hepatic cirrhosis. New Engl. J. Med., 296, 1495-1497 (1977).
76. R. L. Williams, T. F. Blaschke, P. J . Meffin, K. L. Melmon and M. Rowland, Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin. Pharmacol. Ther., 21, 301-309 (1976).
77. A. K.. Miller, J. Adir and R. E. Vestral, Excretion of tolbutamide metabolites in young and old subjects. Eur. J. Clin. Pharmacol., 38, 523-524 (1990).
78. A. S. Gross, B. Heuer and M. Eichelbaum, Stereoselective protein binding of verapamil enantiomers. Biochem. Pharmacol., 37, 4623-4627 (1988).
79. M. Schomerus, B. Spiegelhalder, B. Stieren and M. Eichelbaum, Physiological disposition of verapamil in man. Cardiovasc. Res., 10, 605-612 (1976).
80. S. Toon, L. K. Low, M. Gibaldi, W. F. Trager, R. A. O'Reilly, C. H. Motley and D. A. Goulart, The warfarin-sulfinpyrazone interaction: Stereochemical considerations. Clin. Pharmacol. Ther., 39, 15-24 (1986).
81. E. Chan, M. Pegg, A. S. Mackay, R. B. Cole and M. Rowland, Stereochemical aspects of warfarin in patients receiving chronic therapy. Br. J. Clin. Pharmacol., 19, 571 (1984).
82. A. E. Rettie, A. C. Eddy, L. D. Heimark, M. Gibaldi and W. F. Trager, Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug. Metab. Disposit., 17, 265-270 (1988).
83. W. Kalow, Genetic polymorphism in drug oxidation. Psychopharmacol. Ser., 7, 148-162 (1989).
84. M. S. Lennard, G. T. Tucker and H. F. Woods, The polymorphic oxidation of betaadrenoceptor antagonists. Clin. Pharmacokinet., 11, 1-17 (1986).
85. Y. Sugiyama and T. Iwatsubo, Physiological Pharmacokinetics: Prediction of Human Drug Disposition and Pharmacokinetics from Animal Data and from In Vitro to In Vivo. In Proceedings of the International Symposium on the Role of Drug Metabolism and Pharmacokinetic Research in New Drug Development, Doping Control Center, Korea Institute of Science and Technology (KIST), 1994, pp. 45-63.
86. G. Schuhmann, B. Fichtl and H. Kurtz, Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm. Drug Disposit., 8, 73-76 (1987).
87. Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J. Pharmacokinet. Biopharm., 13, 477-492 (1985).
88. J. H. Lin, Y.Sugiyama, S. Awazu and M. Hanano, Effect of product inhibition on elimination kinetics of ethoxybenzamide in rabbits: Analysis by physiological pharmacokinetic model. Drug Metab. Disposit., 12, 253-256 (1984).
89. S. Miyauchi, Y. Sugiyama, Y. Sawada, K. Morita, T. Iga and M. Hanano, Kinetics of hepatic transport of 4-methylumbelliferone in rats: analysis by multiple indicator dilution method. J. Pharmacokinet. Biopharm., 15, 25-38 (1987).
90. J. R. Gillette and K. S. Pang, Theoretical aspects of pharmacokinetic drug interactions. Clin. Pharmacol. Ther., 22, 623-639 (1977).
91. H. Satoh, Y. Sugiyama, S. Miyauchi, Y. Sawada, T. Iga and M. Hanano, A simulation study on the effect of a uniform diffusional barrier across hepatocytes on drug metabolism by evenly or unevenly distributed uni-enzyme in the liver. J. Pharm. Sci., 75, 3-8 (1986).
92. C. A. Goresky, Initial distribution and rale of uptake of sulfobromophthalein in the liver. Am. J. Physiol., 207, 13-26 (1964).
93. C. A. Goresky and B. E. Nadeau, Uptake of materials by the intact liver. Exchange of glucose across the cell membranes. J. Clin. Invest., 53, 634-646 (1974).
94. C. A. Goresky, A. J. Schwab and K. S. Pang, Kinetic models of hepatic transport at the organ level. In Hepatic Transport and Bile Secretion: Physiology and Pathophysiology, N. Tavoloni and P. D. Berk (Eds), Raven, New York, 1993, pp. 11-39.
95. S. Miyauchi, Y. Sawada, T. Iga, M. Hanano and Y. Sugiyama, Dose-dependent hepatic handling of l-propranolol determined by multiple dilution method: influence of tissue binding of l-propranolol on its hepatic elimination. Biol. Pharm. Bull., 16, 1019-1024 (1993).
96. S. Miyauchi, Y. Sawada, T. Iga, M. Hanano and Y. Sugiyama, Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm. Res., 10, 434-440 (1993).
97. A. J. Schwab, I. A. de-Lannoy, K. Poon, C. A. Goresky and K. S. Pang, Enalaprilat handling by the kidney: barrier-limited cell entry. Am. J. Physiol., 263, F858-869 (1992).
98. C. A. Goresky, K. S. Pang, A. J. Schwab, F. Barker III, W. F. Cherry and G. G. Bach, Uptake of a protein-bound polar compound, acetaminophen sulfate, by perfused rat liver. Hepatol., 16, 173-190 (1992).
99. S. Miyauchi, Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, Conjugative metabolism of 4-methylumbelliferone in the rat liver: verification of the sequestration process in multiple indicator dilution experiments. Chem. Pharm. Bull., 35, 4241-4248 (1987).
100. Y. Sugiyama, H. Sato, S. Yanai, D. C. Kim, S. Miyauchi, Y. Sawada, T. Iga and M. Hanano, Receptor-mediated hepatic clearance of peptide hormones. In Topics in Pharmaceutical Sciences 1989, D. D. Breimer, D. J. A. Crommelin and K. K. Midha (Eds), Elsevier, 1989, pp. 429-443.
101. M. Ichikawa, S. C. Tsao, T. H. Lin, S. Miyauchi, Y. Sawada, T. Iga, M. Hanano and Y. Sugiyama, 'Albumin-mediated transport phenomenon' observed for ligands with high membrane permeability: Effect of the unstirred water layer in the Disse's space of that liver. J. Hepatol., 16, 38-49 (1992).
102. M. Ichikawa, Y. Kato, S. Miyauchi, Y. Sawada, T. Iga, T. Fuwa, M. Hanano and Y. Sugiyama, Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolindine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space. J. Hepatol., 20, 190-200 (1994).
103. A. Martinez-Hernandez, The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver. Lab. Invest., 51, 57-74 (1984).
104. T. Suzuki, S. Isozaki, T. Ishida, Y. Saitoh and F. Nakagawa, Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol. Chem. Pharm. Bull., 22, 1639-1645 (1974).
105. T. Iwatsubo, T. Terasaki, A. Hisaka and Y. Sugiyama, Prediction of non-linearity in hepatic availability in vivo from in vitro data based on physiological pharmacokinetics. In Proceedings of the 9th Annual Meeting of the Japanese Society for the Study of Xenobiotics, 1994, pp. S313.
106. J. J. Gumucio and D. L. Miller, Functional implications of liver cell heterogeneity. Gastroenterology, 80, 393-403 (1981).
107. K. S. Pang and J. A. Terrel, Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. J. Pharmacol. Exp. Ther., 216, 339-346 (1981).
108. K. S. Pang, A review of metabolite kinetics. J. Pharmacokinet. Biopharm., 13, 633-662 (1985).
109. M. Kurita, T. Hamada, Y. Kato and Y. Sugiyama, Optimization analysis of the effect of heterogenous (or, uneven) distribution of diffusional barrier and intrinsic clearance on drug metabolism in the liver. To be submitted.
110. R. Weisiger, J. Gollan and R. Ockner, Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances. Science, 211, 1048-1051 (1981).
111. E. L. Forker and B. A. Luxon, Albumin helps mediate removal of taurocholate by rat liver. J. Clin. Invest., 67, 1517-1522 (1981).
112. E. L. Forker and B. A. Luxon, Albumin-mediated transport of rose bengal by perfused rat liver. Kinetics of the reaction at the cell surface. J. Clin. Invest., 72, 1764-1771 (1983).
113. S. C. Tsao, Y. Sugiyama, Y. Sawada, T. Iga and M. Hanano, Kinetic analysis of albumin-mediated uptake of warfarin by perfused rat liver. J. Pharmacokinet. Biopharm., 16, 165-181 (1988).
114. C. Tsao, Y. Sugiyama, K. Shinmura, Y. Sawada, S. Nagase, T. Iga and M. Hanano, Protein-mediated hepatic uptake of rose-bengal in analbuminemic mutant rats (NAR): albumin is not indispensable to the protein-mediated transport of rose-bengal. Drug Metab. Disposit., 16, 482-489 (1988).
115. A. Weisiger, Dissociation from albumin: a potentially rate limiting step in the clearance of substances by the liver. Proc. Natl Acad. Sci. USA, 82, 1563-1567 (1985).
116. R. A. Weisiger, C. M. Zacks, N. D. Smith and J. L. Boyer, Effect of albumin binding on extraction of sulfobromophthalein by perfused elsamobranch liver: evidence for dissociation limited uptake. Hepatology, 4, 492-501 (1984).
117. L. Bass and S. M. Pond, The puzzle of rates of cellular uptake of protein-bound ligands. In Pharmacokinetics: Mathematical and Statistical Approaches to Metabolism and Distribution of Chemicals and Drugs, A Pecile and A. Rescigno (Eds), Plenum, London, 1987, pp. 241-265.
118. S. C. Tsao, Y. Sugiyama, Y. Sawada, S. Nagase, T. Iga and M. Hanano, Effect of albumin on hepatic uptake of warfarin in normal and analbuminemic mutant rats: Analysis by multiple indicator dilution method. J. Pharmacokinet. Biopharm., 14, 51-64 (1986).
119. F. J. Burczynski, Z. S. Cai, J. B. Moran and E. L. Forker, Palmitate uptake by cultured hepatocytes: albumin binding and stagnant layer phenomena. Am. J. Physiol., 257, G584-593 (1989).
120. E. L. Forker and B. A. Luxon, Effects of unstirred Disse fluid, nonequilibrium binding, and surface mediated dissociation on hepatic removal of albumin-bound organic anions. Am. J. Physiol., 248, G709-717 (1985).
121. T. Horie, T. Mizuma, S. Kasai and S. Awazu, Conformational change in plasma albumin due to interaction with isolated rat hepatocyte. Am. J. Physiol., 254, G465-470 (1988).
122. P. D. Sluijs, B. Postema and D. K. F. Meijer, Lactosylation of albumin reduces uptake rate of dibromosulfophthalein in perfused rat liver and dissociation rate from albumin in vitro. Hepatology, 7, 688-695 (1987).
123. G. Levy, C. M. Lai and A. Yacobi, Comparative pharmacokinetics of coumarin anticoagulants XXXII: Interindividual differences in binding of warfarin and dicumarol in rat liver and implications for physiological pharmacokinetic modeling. J. Pharm. Sci., 67, 229-231 (1978).